Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Masucci, S. Torsteindottir, J. Colombani, C. Brautbar, E. Klein, G. Klein (1987)
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.Proceedings of the National Academy of Sciences of the United States of America, 84 13
T. Sculley, Ann Apolloni, R. Stumm, D. Moss, N. Mueller-Lantczh, I. Misko, D. Cooper (1989)
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.Virology, 171 2
M. Rowe, D. Rowe, C. Gregory, L. Young, P. Farrell, H. Rupani, A. Rickinson (1987)
Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells.The EMBO Journal, 6
(1984)
Site specific mutagenesis of human interleukin-2 gene: structure-function anal'sis s of cystine residues
S. Rosenberg, E. Grimm, M. Mcgrogan, M. Doyle, E. Kawasaki, K. Koths, D. Mark (1984)
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.Science, 223 4643
A. Townsend, J. Rothbard, F. Gotch, G. Bahadur, D. Wraith, A. McMichael (1986)
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptidesCell, 44
M. Epstein, B. Achong (1986)
The Epstein-Barr virus : recent advances
Christopher Gregory, R. Murray, Carole Edwards, A. Rickinson (1988)
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein- Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillanceThe Journal of Experimental Medicine, 167
S. Burrows, I. Misko, T. Sculley, C. Schmidt, D. Moss (1990)
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformantsJournal of Virology, 64
R. Phillips, S. Rowland-Jones, D. Nixon, F. Gotch, J. Edwards, A. Ogunlesi, J. Elvin, J. Rothbard, C. Bangham, C. Rizza, A. McMichael (1991)
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognitionNature, 354
R. Murray, M. Kurilla, J. Brooks, Wendy Thomas, M. Rowe, E. Kieff, A. Rickinson (1992)
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignanciesThe Journal of Experimental Medicine, 176
J. Sample, L. Young, B. Martin, T. Chatman, E. Kieff, A. Rickinson (1990)
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genesJournal of Virology, 64
(1986)
Failure in immunological control of the virus infection: post-transplant lymphomas
R. Khanna, C. Jacob, S. Burrows, M. Kurilla, E. Kieff, I. Misko, T. Sculley, D. Moss (1991)
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.Immunology, 74 3
R. Murray, M. Kurilla, H. Griffin, J. Brooks, M. Mackett, J. Arrand, M. Rowe, S. Burrows, D. Moss, E. Kieff (1990)
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.Proceedings of the National Academy of Sciences of the United States of America, 87
R. Houghten (1985)
General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.Proceedings of the National Academy of Sciences of the United States of America, 82 15
A. Rickinson, M. Rowe, I. Hart, Q. Yao, L. Henderson, H. Rabin, M. Epstein (1984)
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.Cellular immunology, 87 2
D. Moss, I. Misko, S. Burrows, K. Burman, R. McCarthy, T. Sculley (1988)
Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformantsNature, 331
Manuel Kaplan, Manuel Kaplan, C. Clark, C. Clark (1974)
An improved rosetting assay for detection of human T lymphocytes.Journal of immunological methods, 5 2
J. Rothbard, W. Taylor (1988)
A sequence pattern common to T cell epitopes.The EMBO Journal, 7
I. Misko, J. Pope, R. Hütter, T. Soszynski, R. Kane (1984)
HLA‐DR‐antigen‐associated restriction of EBV‐specific cytotoxic T‐cell coloniesInternational Journal of Cancer, 33
(1992)
Role of single amino acids in a human Epstein-Barr-virus specific cytotoxic T cell determinant
C. Schmidt, S. Burrows, T. Sculley, D. Moss, I. Misko (1991)
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.Proceedings of the National Academy of Sciences of the United States of America, 88
(1988)
Novel forms of Epstein-Barr virus persistence . In Immunology and Pathogenesis of Persistent Virus Infections. C. Lopez, editor
T. Dambaugh, K. Hennessy, L. Chamnankit, E. Kieff (1984)
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.Proceedings of the National Academy of Sciences of the United States of America, 81 23
E. Christinck, M. Luscher, Brian Barber, David Williams (1991)
Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysisNature, 352
D. Moss, A. Rickinson, J. Pope (1978)
Long‐term T‐cell‐mediated immunity to epstein‐barr virus in man. I. Complete regression of virus‐induced transformation in cultures of seropositive donor leukocytesInternational Journal of Cancer, 22
A. Rlckinson, D. Moss, J. Pope, N. Ahlberg (1980)
Long‐term T‐cell‐mediated immunity to epstein‐barr virus in man. IV. Development of T‐cell memory in convalescent infectious mononucleosis patientsInternational Journal of Cancer, 25
C. DeLisi, J. Berzofsky (1985)
T-cell antigenic sites tend to be amphipathic structures.Proceedings of the National Academy of Sciences of the United States of America, 82 20
C. Rooney, M. Rowe, L. Wallace, A. Rickinson (1985)
Epstein–Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillanceNature, 317
C. Rooney, A. Rickinson, D. Moss, G. Lenoir, M. Epstein (1985)
Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.IARC scientific publications, 60
There is considerable interest in designing an effective vaccine to the ubiquitous Epstein-Barr virus (EBV). An important role for EBV-specific cytotoxic T lymphocytes (CTLs) in eliminating virus-infected cells is well established. Limited studies using a small number of immune donors have defined target epitopes within the latent antigens of EBV. The present study provides an extensive analysis of the distribution of class I-restricted CTL epitopes within EBV-encoded proteins. Using recombinant vaccinia encoding individual EBV latent antigens (Epstein-Barr nuclear antigen EBNA 1, 2, 3A, 3B, 3C, LP, and LMP 1), we have successfully localized target epitopes recognized by CTL clones from a panel of 14 EBV-immune donors. Of the 20 CTL epitopes localized, five were defined at the peptide level. Although CTL clones specific for nine epitopes recognized both type 1 and type 2 transformants, a significant number of epitopes (7/16 epitopes for which EBV type specificity was determined) were detected only on type 1 EBV transformants. Vaccinia recombinants encoding EBNA 3A and EBNA 3C were recognized more frequently than any other vaccinia recombinants used in this study, while no CTL epitopes were localized in EBNA 1. Surprisingly, epitope specificity for a large number of EBV-specific CTL clones could not be localized, although vaccinia recombinants used in this study encoded most of the latent antigens of EBV. These results suggest that any EBV vaccine based on CTL epitopes designed to provide widespread protection will need to include not only latent antigen sequences but also other regions of the genome. The apparent inability of human CTLs to recognize EBNA 1 as a target antigen, often the only latent antigen expressed in Burkitt's lymphoma and nasopharyngeal carcinoma, suggests that EBV-specific CTL control of these tumors will not be feasible unless the down-regulation of latent antigens can be reversed.
The Journal of Experimental Medicine – Rockefeller University Press
Published: Jul 1, 1992
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.